The MRI Signature of Neuroendocrine Liver Metastases: Toward a Radiologic Identikit
Background: Neuroendocrine neoplasms are frequently diagnosed after the detection of liver metastases, often when the primary tumor remains occult. Accurate non-invasive differentiation of neuroendocrine liver metastases (NELMs) from other focal hepatic lesions is therefore crucial. This study aimed to characterize the magnetic resonance imaging (MRI) features of NELMs using hepatocyte-specific contrast agents and to identify a potential radiologic “signature” that may suggest a neuroendocrine origin. Methods: This retrospective study included three cohorts: patients with histologically confirmed NELMs (n = 51; 146 lesions), patients with colorectal cancer liver metastases (n = 18; 46 lesions), and patients with benign hepatic hemangiomas (n = 28; 51 lesions). All subjects underwent standardized liver MRI with Gd-EOB-DTPA. Lesions were evaluated for size, diffusion-weighted imaging characteristics, apparent diffusion coefficient values, arterial-phase enhancement, T2-weighted signal, hepatobiliary-phase appearance, and hemorrhagic components. Statistical analyses included univariate and multivariate testing and receiver operating characteristic curve analysis. Results: NELMs commonly demonstrated arterial hyperenhancement, diffusion restriction, and variable T2 and hepatobiliary-phase signal heterogeneity. Compared with colorectal metastases and hemangiomas, NELMs showed distinctive patterns, particularly higher rates of hepatobiliary-phase heterogeneity and arterial enhancement. Lesion size, ADC metrics, T2 heterogeneity, and hemorrhage were significant discriminators. Conclusions: Hepatocyte-specific MRI enables identification of characteristic imaging features of NELMs. An integrated assessment of morphologic, diffusion, and hepatobiliary-phase findings may facilitate early recognition of neuroendocrine metastases, even when the primary tumor is unknown, improving diagnostic confidence and clinical management.
Authors
- Laura Bergamasco (ORCID: https://orcid.org/0000-0002-0160-0898)
- Alessandro Serafini (ORCID: https://orcid.org/0000-0002-4992-4824)
- Riccardo Faletti (ORCID: https://orcid.org/0000-0002-8865-8637)
- Clara Gaetani (ORCID: https://orcid.org/0000-0001-9303-4397)
- Stefano Cirillo
- Paolo Fonio
- Teresa Gallo (ORCID: https://orcid.org/0000-0003-0476-9100)
- Marco Gatti
Institutions
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- A. O. Ordine Mauriziano di Torino (IT)
- Candiolo Cancer Institute (IT)
Publication Details
- Journal
- Livers
- Published
- 2026-05-12
- DOI
- https://doi.org/10.3390/livers6030041
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00